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Summary
Patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome
(MDS) may respond to treatment with epigenetic-modifying agents. His-
tone deacetylase inhibitors may synergize with hypomethylating agents.
This phase 1 dose-escalation study was designed to determine the maxi-
mum tolerated dose, recommended phase 2 dose, safety and tolerability of
vorinostat plus decitabine in patients with relapsed/refractory AML, newly-
diagnosed AML, or intermediate- to high-grade MDS. Thirty-four patients
received concurrent therapy with decitabine plus vorinostat and 37 received
sequential therapy with decitabine followed by vorinostat. Twenty-nine
patients had relapsed/refractory AML, 31 had untreated AML and 11 had
MDS. The target maximum administered dose (MAD) of decitabine
20 mg/m2 daily for 5 d plus vorinostat 400 mg/d for 14 d was achieved for
concurrent and sequential schedules, with one dose-limiting toxicity (Grade
3 QTc prolongation) reported in the sequential arm. Common toxicities
were haematological and gastrointestinal. Responses were observed more
frequently at the MAD on the concurrent schedule compared with the
sequential schedule in untreated AML (46% vs. 14%), relapsed/refractory
AML (15% vs. 0%) and MDS (60% vs. 0%). Decitabine plus vorinostat
given concurrently or sequentially appears to be safe and well-tolerated.
Concurrent therapy shows promising clinical activity in AML or MDS,
warranting further investigation.
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Epigenetic-modifying agents offer a new treatment option for
previously challenging disorders. The spectrum of diseases
encompassed by myelodysplastic syndrome (MDS) and acute
myeloid leukaemia (AML) appear to be responsive to this
class of agents, with multiple trials showing clinical activity
to agents that are able to induce global hypomethylation
(Blum et al, 1997; Wijermans et al, 2005; Cashen et al, 2010;
Lubbert et al, 2011). Hypomethylation reverses the effects of
aberrant epigenetic promoter suppression, and evidence sug-
gests that broadening the ability to inhibit repressive signals
at the chromatin level might lead to enhanced normalization
of regulatory protein expression and increased proapoptotic
activity, leading to greater tumour cell death (Yoo & Jones,
2006; Soriano et al, 2007).
The nucleoside analog decitabine (Dacogen; Eisai Inc.,
Dublin, CA, USA), 5-aza-20-deoxycytidine, is believed to have
anticancer activity by incorporating into DNA and
forming an irreversible covalent complex with DNA
(cytosine-5-)-methyltransferase 1 (DNMT1) (Hurd et al,
1999), causing degradation and depletion of the enzyme,
which leads to hypomethylation of aberrantly hypermethylat-
ed promoters. This may then allow for the reactivation of
silenced tumour suppressor genes and regulatory microRNA.
However, demethylation alone is not adequate to restore
expression of certain genes, and broader epigenetic modula-
tion may lead to enhanced antitumour activity (Cameron
et al, 1999; Si et al, 2010). Consequently, the addition of a
histone deacetylase (HDAC) inhibitor to a decitabine regi-
men seems to be a rational combination. Preclinical evidence
supports the use of HDAC inhibitors in haematological
malignancies. HDAC inhibitors as single agents have been
previously shown to affect a host of cellular targets and pro-
cesses that might lead to antitumour activity in myeloid
malignancies (eg, angiogenesis, apoptosis, the cell cycle, and
tumour immunology) and have shown in vitro synergy with
hypomethylating agents in various tumour types (Johnstone,
2002; Fiskus et al, 2009).
In pilot studies, the combination of the methyltransferase
inhibitor azacitidine and the HDAC inhibitor sodium phen-
ylbutyrate led to clinical benefit or major cytogenetic
responses in patients with AML or MDS (Gore et al, 2006;
Maslak et al, 2006). In vitro, simultaneous treatment with
decitabine and the investigational HDAC inhibitor MS-275
induces apoptosis in AML cell lines (Nishioka et al, 2011).
Moreover, in a phase 1/2 trial, combined therapy with deci-
tabine and the HDAC inhibitor valproic acid was safe and
led to objective responses in patients with AML or MDS
(Garcia-Manero et al, 2006). Vorinostat (suberoylanilide hy-
droxamic acid; Zolinza; Merck & Co., Inc.; Whitehouse Sta-
tion, NJ, USA), an orally bioavailable synthetic hydroxamic
acid class HDAC inhibitor, has both histone and protein de-
acetylase activity. Activity of vorinostat as single agent or in
combination therapy in leukaemia has been demonstrated in
vitro and in rodent models (Nimmanapalli et al, 2003; Yu
et al, 2003; Reddy et al, 2004; Sanchez-Gonzalez et al, 2006;
Shiozawa et al, 2009). In a phase 1 trial, treatment with vori-
nostat (100–300 mg administered twice or three times daily
for 14 d) resulted in haematological improvement (HI) in
seven patients with AML (Garcia-Manero et al, 2008), and
therefore was a good candidate for use in combination with
the hypomethylating agent decitabine. The primary objective
of this phase 1 study was to determine the maximum toler-
ated dose (MTD), the recommended phase 2 dose (RP2D),
and the safety and tolerability of vorinostat administered
concurrently or sequentially with decitabine in patients with
relapsed/refractory AML, newly diagnosed elderly patients
with AML and patients with intermediate- to high-grade
MDS.
Methods
Patients and trial design
This was a phase 1, multicentre, open-label, nonrandomized,
two-cohort dose-escalating trial (ClinicalTrials.gov identifier:
NCT00479232; http://clinicaltrials.gov/ct2/show/NCT00479232;
Protocol 055). Patients 18 years or older with MDS (Interna-
tional Prognostic Scoring System intermediate 1 and above)
or relapsed/refractory AML were eligible. Patients aged
60 years and older with newly diagnosed AML were also eligi-
ble if not a candidate for cytotoxic chemotherapy. Other
inclusion criteria included an Eastern Cooperative Oncology
Group performance status of ≤2, prior therapy (chemother-
apy, biological therapy or investigational therapy other than
hydroxycarbamide) that was completed a minimum of
4 weeks before study entry and standard criteria for organ
function. There were no minimal haematological parameter
requirements before enrollment; however, patients could not
be refractory to platelet transfusions. Patients were excluded if
they had a history of prior decitabine or azacitidine exposure
or previous treatment with an HDAC inhibitor (except for
valproic acid for epilepsy, in which case a 30-d washout was
mandatory).
All patients received decitabine at a dose of 20 mg/m2
infused intravenously over 1 h on days 1–5 of a 28-d cycle.
Patients were simultaneously enrolled in cohorts of 3 to
either concurrent or sequential treatment with decitabine as
per the standard 3 + 3 phase 1 study design (Fig 1). For the
concurrent vorinostat regimen, dose levels started at 400 mg
administered orally (PO) daily on days 1–7 with 21 d free; if
tolerable, dose level 2 added 7 d of vorinostat 400 mg PO
daily on days 15–21 of a 28-d cycle. If dose level 2 was toler-
ated, dose level 3 was added: patients were dosed with vori-
nostat at 400 mg PO daily for 14 consecutive days on days
1–14. For the sequential arm, dose level 1a patients received
vorinostat at 400 mg PO daily on days 6–12. If tolerable, the
vorinostat dose was escalated (dose level 2a) for 10 d (days
6–15). For dose level 3a, vorinostat was administered for
14 d (days 6–19). No intrapatient dose escalation was
permitted and patients did not receive additional cycles of
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therapy earlier than 4–6 weeks from the start of the previous
cycle. Grade 3–4 non-haematological toxicities according
to Common Terminology Criteria for Adverse Events
(CTCAE) version 3 (http://ctep.cancer.gov/protocolDevelop-
ment/electronic_applications/docs/ctcaev3.pdf) were defined
as dose-limiting toxicities (DLTs), as well as prolonged myel-
osuppression (>42 d in absence of active disease on marrow
examination), and led to defined dose modifications for
future cycles. Bone marrow aspiration and biopsy was per-
formed on patients within 14 d of commencing treatment
and on days 21 and 28 of the first cycle, and aspiration on
day 28 of cycle 2 and subsequently as clinically indicated.
Dose escalation proceeded if none of the three patients in
the cohort had a first cycle DLT. If one of the three patients
in a cohort experienced a DLT, three more patients were
accrued at that dose level. In the event that a second patient
experienced a DLT, that is, two or more out of six patients,
then patients were accrued to the next lower dose level. The
MTD was defined as that at which no more than one patient
out of six experienced a DLT during the first cycle of treat-
ment. Patients with MDS and AML were enrolled to both
arms initially, with an expansion at the maximum adminis-
tered dose (MAD) for MDS, untreated AML or relapsed/
refractory AML. With at least 14 patients accrued to the two
AML groups, the upper limit of the 80% confidence interval
for DLT rate excludes a rate of 33% if two or fewer patients
develop DLTs.
The trial protocol was reviewed and approved by the insti-
tutional review board and ethics committee at each site
before patients were allowed to enrol. This trial was con-
ducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines.
Study objectives and assessments
The primary objectives were to determine the MTD, RP2D
and overall safety and tolerability for the combination of
vorinostat with decitabine. An exploratory objective was to
assess clinical activity of the combination of vorinostat and
decitabine; efficacy end points included objective response
rate, time to response, and progression-free survival for AML
patients, and time to leukaemic transformation or death for
MDS patients. Clinical responses were measured according to
the International Working Group criteria established for
AML and MDS, and included complete remission (CR), par-
tial remission (PR), and HI (Cheson et al, 2003, 2006).
Patients’ cytogenetics were also assessed and categorized as
poor, intermediate, or good risk according to European Leu-
kaemiaNet criteria (D€ohner et al, 2010). Patients received
treatment until disease progression, unacceptable toxicity or
withdrawal of consent up to 24 months (two patients
received treatment beyond 24 months because they were
benefiting from treatment).
Results
Patient disposition and baseline characteristics
Eighty-four patients were screened between June 2007 and
May 2010; 71 patients received the combination of decitabine
plus vorinostat – 34 patients on the concurrent arm and 37
patients on the sequential arm. Twenty-nine patients had
relapsed/refractory AML, 31 patients had previously untreated
AML, and 11 patients presented with MDS. Most patients with
relapsed/refractory AML had received cytarabine plus idarubi-
cin hydrochloride [11 (38%)] or single-agent cytarabine [9
(31%)]. Among the 42 patients with intermediate- to high-risk
MDS or untreated AML, 38 (91%) had not received any prior
therapy. The median age of the overall group was 68 years
(range 18–85 years). Patient characteristics were similar in the
two cohorts, other than an increased number of male patients
in the concurrent group (Table I).
Safety and tolerability of vorinostat plus decitabine
Patients treated on the concurrent and sequential arm were
exposed to a mean of 43 cycles and 29 cycles, respectively.
The MAD of vorinostat plus decitabine in either arm was
400 mg daily PO for 14 consecutive days in a 28-d cycle.
There was only one first cycle DLT (grade 3 QTc prolonga-
12 Days 84 282420 16 0
 Decitabine
20 mg/m2 IV
Days 1–5
Treatment cycle 
Dose 
level 
 Days 1–7 1 
Concurrent
VOR 400 mg
QD  
Days 1–7 Days 15–21 Days 8–14 (off) 2 
Days 1–14 3 
Days 6–12 1a 
Days 6–19 3a 
Sequential
VOR 400 mg
QD 
Days 6–15 2a 
Fig 1. Concurrent and sequential dosing
schedules of vorinostat in 28-d treatment
cycles. Note that all patients initially received
20 mg/m2 decitabine. VOR, vorinostat; QD,
every day.
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tion from 461 ms at baseline to 592 ms on day 8), observed
in a patient treated at the MAD on the sequential arm. In
both arms, the MAD was reached before the MTD was estab-
lished. Two of 34 patients (6%) in the concurrent arm and 3
of 37 patients (8%) in the sequential arm required one dose
modification due to adverse events (AEs). The number of
patients requiring two or more dose modifications due to
AEs was 1 (3%) in the concurrent arm and 3 (8%) in the
sequential arm. Most patients in both the concurrent arm
(91%) and sequential arm (84%) did not need any dose
reductions. Nine patients of 61 (15%) treated at the MAD
required dose reductions due to AEs; 3/31 (10%) concurrent,
6/30 (20%) sequential. Median time on therapy at the MAD,
before requiring dose reduction, for patients on the concur-
rent and sequential regimens was 150 d (range: 9–67 d) and
1365 d (range: 48–225 d), respectively.
Drug-related AEs were reported in 89% of patients
(Table II). The most common drug-related AEs (all grades)
reported in more than 20% of patients across both regimens
were nausea (59%), diarrhoea (41%), fatigue (40%), vomit-
ing (30%), decreased appetite (25%), thrombocytopenia
(24%) and leucopenia (23%). The most common Grade 3
or higher AEs were haematological toxicities, including
thrombocytopenia (21%), leucopenia (21%), neutropenia
(18%) and febrile neutropenia (16%). While more haemato-
logical toxicities were reported in the concurrent arm
(Table IIIA) compared with the sequential arm, fatigue was
more common in the sequential arm (Table IIIB) compared
with the concurrent arm. There were two cardiovascular
drug-related grade 3 or above AEs reported in five patients:
one Grade 4 cardiac arrest reported in Cycle 2 of sequential
14 d vorinostat + decitabine during an episode of urosepsis,
and one Grade 3 tachycardia reported in Cycle 5 of concur-
rent 14 d vorinostat + decitabine. Serious AEs (SAEs) were
reported in 78% of patients (30% of patients had drug-
related SAEs). The most commonly reported drug-related
SAE occurring in >10% of patients was febrile neutropenia
(13%). More SAEs were reported in the concurrent arm
compared with the sequential arm. AEs were the reason for
discontinuation in 20% of patients; SAEs were the reason for
discontinuation in 17% of patients and 6% discontinued
treatment due to drug-related AEs. During treatment and
protocol-defined follow-up of up to 24 months after receiv-
ing first dose of therapy, deaths were reported in 11% of
patients, but none of the deaths were considered drug-
related. Deaths were due to AML, pneumonia, lung infection,
cerebrovascular accident, and staphylococcal bacteraemia.
Clinical activity of vorinostat plus decitabine treatment
Clinical activity with the concurrent and sequential dosing
schedules was assessed among the three disease states
(relapsed/refractory AML, newly diagnosed AML, and inter-
mediate- to high-grade MDS) as an exploratory objective
(Table IV). At the MAD dose level, in the concurrent arm,
there were six responders (four CRs, two PRs) out of 13
patients (46%) with untreated AML, while in the sequential
Table I. Patient baseline characteristics.
Patient
characteristic
Vorinostat + decitabine
Total
N = 71
Concurrent
cohort
n = 34
Sequential
cohort
n = 37
Gender, n (%)
Male 23 (68) 19 (51) 42 (59)
Female 11 (32) 18 (49) 29 (41)
Age, years
Mean (SD) 639 (130) 666 (138) 653 (134)
Median
(range)
680
(330–800)
710
(180–850)
680
(180–850)
Race, n (%)
White 30 (88) 34 (92) 64 (90)
Black 2 (6) 1 (3) 3 (4)
Asian 1 (3) 2 (5) 3 (4)
Other 1 (3) 0 1 (1)
ECOG performance status, n (%)
0 14 (41) 8 (22) 22 (31)
1 14 (41) 24 (65) 38 (54)
2 6 (18) 5 (14) 11 (16)
Disease characteristic, n (%)
Refractory or
relapsed AML
14 (41) 15 (41) 29 (41)
Untreated AML 15 (44) 16 (43) 31 (44)
Intermediate
or high risk
MDS
5 (15) 6 (16) 11 (16)
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group;
AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome.
Table II. Treatment-related adverse events of any grade reported in at
least 10% of patients in any treatment group (all patients as treated).
Adverse event, n (%)
Concurrent
(n = 34)
Sequential
(n = 37)
Total
(N = 71)
Nausea 19 (56) 23 (62) 42 (59)
Diarrhoea 16 (47) 13 (35) 29 (41)
Fatigue 11 (32) 17 (46) 28 (40)
Vomiting 12 (35) 9 (24) 21 (30)
Decreased appetite 9 (27) 9 (24) 18 (25)
Thrombocytopenia 11 (32) 6 (16) 17 (24)
Leucopenia 11 (32) 5 (14) 16 (23)
Neutropenia 9 (27) 4 (11) 13 (18)
Febrile neutropenia 6 (18) 5 (14) 11 (16)
Asthenia 3 (9) 5 (14) 8 (11)
Hyperglycaemia 4 (12) 5 (14) 9 (13)
Hypokalaemia 5 (15) 4 (11) 9 (13)
Dizziness 3 (9) 4 (11) 7 (10)
Hypoalbuminaemia 4 (12) 2 (5) 6 (9)
Constipation 2 (6) 4 (11) 6 (9)
Hyponatraemia 4 (12) 0 4 (6)
M. Kirschbaum et al
188 ª 2014 John Wiley & Sons Ltd
British Journal of Haematology, 2014, 167, 185–193
arm there were two CRs among 14 patients (14%). Two
patients met the criteria for HI following sequential treat-
ment at the MAD. Among patients with relapsed/refractory
AML, there were two CRs out of 13 patients (15%) in the
concurrent arm, while there were no responses observed on
the sequential arm among the 15 patients treated at the
MAD. One patient in the concurrent arm achieved HI.
Among patients with MDS, three objective responses (one
CR, two PRs) were observed among five patients (60%) in
the concurrent arm and one patient had HI. There were no
Table III. Grade 3–4 drug-related adverse events reported in patients treated with vorinostat and decitabine (A) concurrently (all patients as trea-
ted) and (B) sequentially (all patients as treated).
Adverse event, n (%)
Vorinostat 400 mg qd 9
7 d/4 weeks + decitabine
n = 3
Vorinostat 400 mg qd 9
7 d/2 weeks + decitabine
n = 3
Vorinostat 400 mg qd 9
14 d/4 weeks + decitabine
n = 28
(A)
Anaemia 0 (0) 0 (0) 1 (36)
Aspartate aminotransferase increased 0 (0) 0 (0) 1 (36)
Cellulitis 0 (0) 0 (0) 1 (36)
Decreased appetite 0 (0) 0 (0) 1 (36)
Deep vein thrombosis 0 (0) 0 (0) 1 (36)
Fatigue 0 (0) 0 (0) 1 (36)
Febrile neutropenia 0 (0) 0 (0) 8 (286)
Haematmesis 0 (0) 0 (0) 1 (36)
Hypermagnesaemia 1 (333) 0 (0) 0 (0)
Hypokalaemia 0 (0) 0 (0) 2 (71)
Hyponatraemia 0 (0) 0 (0) 3 (107)
Leucopenia 0 (0) 2 (667) 8 (286)
Nausea 0 (0) 0 (0) 2 (71)
Neutropenia 0 (0) 1 (333) 8 (286)
Pancytopenia 0 (0) 0 (0) 1 (36)
Pneumonia 0 (0) 0 (0) 3 (107)
Pneumonia fungal 0 (0) 0 (0) 1 (36)
Tachycardia* 0 (0) 0 (0) 1 (36)
Thrombocytopenia 0 (0) 1 (333) 9 (391)
Vomiting 0 (0) 0 (0) 1 (36)
Adverse event, n (%)
Vorinostat 400 mg qd 9
7 d/4 weeks + decitabine
n = 3
Vorinostat 400 mg qd 9
10 d/4 weeks + decitabine
n = 4
Vorinostat 400 mg qd 9
14 d/4 weeks + decitabine
n = 30
(B)
Anaemia 0 (0) 1 (250) 0 (0)
Aspartate aminotransferase increased 0 (0) 0 (0) 1 (33)
Cardiac arrest 0 (0) 0 (0) 1 (33)
Decreased appetite 0 (0) 0 (0) 2 (67)
Diarrhoea 0 (0) 0 (0) 1 (33)
Dizziness 0 (0) 0 (0) 1 (33)
ECG QT prolonged† 0 (0) 0 (0) 2 (67)
Fatigue 0 (0) 0 (0) 5 (167)
Febrile neutropenia 0 (0) 0 (0) 5 (167)
Hyperglycaemia 0 (0) 0 (0) 1 (33)
Hypertension 0 (0) 0 (0) 1 (33)
Hypotension 0 (0) 0 (0) 2 (67)
Leucopenia 1 (333) 1 (250) 3 (100)
Mucosal inflammation 0 (0) 0 (0) 1 (33)
Neutropenia 1 (333) 0 (0) 4 (133)
Renal failure, acute 0 (0) 0 (0) 1 (33)
Thrombocytopenia 1 (333) 1 (250) 3 (100)
ECG, electrocardiogram.
*Grade 3 reported in cycle 5, not treated as a dose limiting toxicity.
†One Grade 3 incident reported in cycle 1 was treated as a dose-limiting toxicity.
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responses observed among the six MDS patients treated on the
sequential regimen at the MAD. There was one additional
responder not treated at the MAD: a patient with untreated
AML in the concurrent arm who achieved a CR. Six patients
who did not have a formal response remained on treatment
for more than 6 months: two patients with untreated AML on
the sequential arm, three patients with MDS on the sequential
arm and one patient on the concurrent arm with refractory or
relapsed AML (all treated at the MAD).
The median time from treatment start to stop (treatment
duration) was 70 d (range 2–815). At the MAD, the median
duration was 80 d, vs. 435 at the lower doses (P = NS).
There were 14 responders, with a median treatment duration
of 224 d (range 27–815); one patient with a CR withdrew on
day 27 due to AEs, and a patient with a CR went off study
at 815 d but did not relapse for a total of 1465 d. Eight of
14 responders had median treatment duration of more than
6 months. Median treatment duration for the entire
untreated AML cohort was 110 d (range 2–557), for relapsed
or refractory AML was 46 d (range 6–349), and for MDS
was 119 d (range 13–815; Fig 2). At the MAD, the concur-
rent arm had median treatment duration of 101 d (2–815),
compared with 54 d (8–712) for the sequential arm
(P = NS). The role of cytogenetic aberrations on response to
treatment was also evaluated. In the untreated AML group
there were three responders out of eight patients with poor
risk cytogenetics, and there was one responder out of 11
patients with poor risk cytogenetics in the relapsed or refrac-
tory AML group. There were no responders in the poor risk
cytogenetics group among the three patients with MDS trea-
ted with vorinostat plus decitabine (Table V).
Discussion
We studied the combination of two epigenetic agents, vorino-
stat and decitabine, administered either sequentially or con-
currently, in older patients with untreated AML, patients with
relapsed/refractory AML and intermediate- to high-grade
MDS patients. Both schedules were reasonably well tolerated –
only one QTc prolongation DLT was observed in the sequen-
tial arm. The MAD of 400 mg vorinostat administered PO
daily for 14 consecutive days whether concurrently with or
sequentially after 5 d of decitabine in a 28-d cycle was reached;
therefore, the MTD was not established. The most severe AEs
were haematological, which included thrombocytopenia, leu-
copenia and neutropenia. Based on the toxicity profile
observed with vorinostat and decitabine, the combination
could be considered for future investigation in patients with
AML or MDS, with concurrent therapy showing the most
promising clinical activity.
While the primary objective of this phase 1 study was to
establish toxicity of vorinostat treatment in combination with
decitabine, a secondary end point of the trial was to conduct
a preliminary assessment of the treatment sequence. Epige-
netic repression of transcription is a complex process that is
mediated by a large number of enzymatic processes at the
level of histones (acetylation, methylation, ubiquitination,
etc.) and that directly affects genes via DNA methylation. A
suggestion that DNA methylation was the primary effect was
first demonstrated with respect to certain hypermethylated
genes, which showed synergistic reversal of repression when
treatment was initiated with a hypomethylating agent fol-
lowed by an HDAC inhibitor, but not concurrently or with
an HDAC inhibitor alone (Cameron et al, 1999).
In this trial, while the number of patients was small, there
were more responses observed in patients treated concur-
rently rather than sequentially with vorinostat and decitabine
in all disease states tested, with a notable increase in response
among patients with untreated AML at the MAD level. This
trend was also observed in the relapsed/refractory AML
patient cohort and the MDS group. Responses were seen
even among patients with poor risk cytogenetics – three of
six in the untreated AML cohort and all three on the concur-
rent arm. While the clinical data stand on their own, it is
possible to explain the disparity between the in vitro and in
vivo results biologically as well; in the preclinical model, it is
the expression of certain genes that show increased reactiva-
tion with the sequence, while other genes may require a dif-
ferent sequence for reactivation (Jiang et al, 2007). It is also
possible that a significant contribution to the activity of deci-
tabine is through a direct cytotoxic effect rather than an epi-
genetic one, and the effect of vorinostat is to enhance
cytotoxicity via its effect upon DNA damage response ele-
ments such as TP53 or GADD45A (Kretzner et al, 2011).
Despite the encouraging clinical results, the optimal dose
and schedule of decitabine remain unclear. A previous study
in older patients with AML found a decitabine dosing sche-
dule of 20 mg/m2 for 5 d resulted in an overall response rate
of 25% in a larger group of 55 patients (Cashen et al, 2010).
In another study, a regimen of 15 mg/m2 given three times
daily over 3 d every 6 weeks led to an overall response rate
of 26% in untreated AML patients (Lubbert et al, 2011),
which was similar to the 20 mg/m2 over 5 d regimen, while
the use of 20 mg/m2 administered daily to patients with
untreated or relapsed AML for 10 d showed increased activ-
ity with an overall response rate of 64% (Blum et al, 1997).
Table IV. Objective responses at the maximum administered dose
(decitabine 20 mg/m2 for 5 d plus vorinostat 400 mg/d for 14 d*).
Myeloid disease
Concurrent cohort Sequential cohort
n
Objective
responses n
Objective
responses
Untreated AML 13 6 (4 CRs, 2 PRs) 14 2 (2 CRs)
Relapsed or
refractory AML
13 2 (2 CRs) 10 0
MDS 5 3 (1 CR, 2 PRs) 6 0
AML, acute myeloid leukaemia; CR, complete remission; PR, partial
remission; MDS, myelodysplastic syndrome.
*14 d every 4 weeks or in three cases, 7 d every 2 weeks.
M. Kirschbaum et al
190 ª 2014 John Wiley & Sons Ltd
British Journal of Haematology, 2014, 167, 185–193
Based on these reports, a phase 1 study combining vorinostat
given concurrently with the 10-d schedule of decitabine
would be of interest. Additionally, the optimum dosing sche-
dule of vorinostat still needs to be fully elucidated. In this
study, the 400 mg/d dose was used, as this is the US Food
and Drug Administration–approved dose for cutaneous T
cell lymphoma. However, the half-life of the drug is short, so
studies were subsequently done using more frequent dosing
regimens, such 200 mg PO twice a day or three times a day
(Garcia-Manero et al, 2008; Kirschbaum et al, 2011). These
dosing schedules demonstrated single-agent activity in indo-
lent lymphoma, as well as leukaemia and MDS, and should
be studied in combination with decitabine.
In summary, the addition of the HDAC inhibitor vorino-
stat at 400 mg/d for 14 d in either a concurrent or sequential
dosing schedule to a 5-d regimen of the hypomethylating
agent decitabine at 20 mg/m2 was feasible and tolerable in
patients with AML and MDS. Although the number of
patients evaluated in the two dosing schedules was small, our
study showed enhanced activity for the concurrent schedule
over the sequential dosing schedule. These results support
further evaluation of the concurrent schedule in a large phase
2 study, with correlative studies designed to better under-
stand the interrelationship of hypomethylation and HDAC
inhibition, two biologically and clinically important epige-
netic processes.
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